SCHEMBL24460764

SCHEMBL24460764

Nc1c(C(=O)O)cnn1CC1CCOCC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.52
EED O75530 1/20 0.45
RBBP4 Q09028 1/20 0.45
SUZ12 Q15022 1/20 0.45
EZH2 Q15910 1/20 0.45
AEBP2 Q6ZN18 1/20 0.45
PKM P14618 1/20 0.41
PDE8B O95263 1/20 0.39
ALDH1A1 P00352 2/20 0.38
KDM4E B2RXH2 1/20 0.38
ADORA2A P29274 1/20 0.36
CNR1 P21554 3/20 0.36
CNR2 P34972 3/20 0.36
PDE4B Q07343 1/20 0.36
BRS3 P32247 1/20 0.36
NR3C1 P04150 1/20 0.36
FEN1 P39748 1/20 0.36
TSHR P16473 1/20 0.35
NOTUM Q6P988 1/20 0.35
IDH1 O75874 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31352138 0.90 LMNA (0.58) LMNAEEDRBBP4SUZ12EZH2
SCHEMBL31352123 0.87 LMNA (0.62) LMNAPKMALDH1A1KDM4ETSHR
SCHEMBL31352157 0.87 LMNA (0.66) LMNAPKMALDH1A1KDM4EADORA2A
SCHEMBL27032676 0.82 LMNA (0.78) LMNAEEDRBBP4SUZ12EZH2
SCHEMBL30600060 0.80 LMNA (0.75) LMNAEEDRBBP4SUZ12EZH2
SCHEMBL25857669 0.77 PKM (0.44) LMNAEEDRBBP4SUZ12EZH2
SCHEMBL23273712 0.76 HTT (0.44) LMNAEEDRBBP4SUZ12EZH2
SCHEMBL15997729 0.76 CNR2 (0.45) CNR1CNR2
SCHEMBL1958192 0.72 FEN1 (0.40) EEDRBBP4SUZ12EZH2AEBP2
SCHEMBL24758344 0.72 EED (0.37) EEDRBBP4SUZ12EZH2AEBP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240025917-A1 PLASMA KALLIKREIN INHIBITORS MERCK SHARP & DOHME LLC (US) 2024-01-25 US disclosed
US-20240025917-A1 PLASMA KALLIKREIN INHIBITORS MERCK SHARP & DOHME LLC (US) 2024-01-25 US disclosed
US-20240025917-A1 PLASMA KALLIKREIN INHIBITORS MERCK SHARP & DOHME LLC (US) 2024-01-25 US disclosed
CN-116917293-A Plasma kallikrein inhibitors 默沙东有限责任公司 2023-10-20 CN disclosed
WO-2022109161-A1 PLASMA KALLIKREIN INHIBITORS MERCK SHARP & DOHME CORP. (US) 2022-05-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240025917-A1 PLASMA KALLIKREIN INHIBITORS KLKB1, SERPINE1, KLK5 LMNA 2426/4885EED 3819/4885RBBP4 3510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.